Gilead Sciences Inc

GILD: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|h#LOCK|L^LOCK|$&S$#b

Gilead Earnings: Our $108 Fair Value Reflects Solid Underlying HIV Demand Growth and Margin Strength

Gilead reported 6% product sales growth in 2024, and excluding a first-quarter charge for the CymaBay Therapeutics acquisition, saw a 43% non-GAAP operating margin and 15% non-GAAP EPS growth. Gilead guided for a flat to slight 1% drop in sales in 2025 with operating margins improving to about 45%.

Sponsor Center